The stock of Intellia Therapeutics Inc (NTLA) has seen a 2.25% increase in the past week, with a -5.01% drop in the past month, and a -31.87% decrease in the past quarter. The volatility ratio for the week is 10.13%, and the volatility levels for the past 30 days are at 8.98% for NTLA. The simple moving average for the last 20 days is -10.65% for NTLA stock, with a simple moving average of -47.98% for the last 200 days.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
The stock has a 36-month beta value of 2.11. Opinions on the stock are mixed, with 17 analysts rating it as a “buy,” 4 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for NTLA is 97.42M, and at present, short sellers hold a 25.07% of that float. On March 12, 2025, the average trading volume of NTLA was 3.15M shares.
NTLA) stock’s latest price update
Intellia Therapeutics Inc (NASDAQ: NTLA) has seen a decline in its stock price by -1.69 in relation to its previous close of 9.46. However, the company has experienced a 2.25% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-11 that NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135389&wire=1 or contact Joseph E. Levi, Esq.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with H.C. Wainwright repeating the rating for NTLA by listing it as a “Buy.” The predicted price for NTLA in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on March 05, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $13, previously predicting the price at $45. The rating they have provided for NTLA stocks is “Neutral” according to the report published on February 28th, 2025.
Goldman gave a rating of “Sell” to NTLA, setting the target price at $9 in the report published on February 28th of the current year.
NTLA Trading at -12.18% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.10% of loss for the given period.
Volatility was left at 8.98%, however, over the last 30 days, the volatility rate increased by 10.13%, as shares sank -2.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.82% lower at present.
During the last 5 trading sessions, NTLA rose by +2.25%, which changed the moving average for the period of 200-days by -63.83% in comparison to the 20-day moving average, which settled at $10.41. In addition, Intellia Therapeutics Inc saw -20.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Clark Eliana, who sale 679 shares at the price of $8.99 back on Mar 04 ’25. After this action, Clark Eliana now owns 95,369 shares of Intellia Therapeutics Inc, valued at $6,104 using the latest closing price.
BASTA JAMES, the EVP, General Counsel of Intellia Therapeutics Inc, sale 2,572 shares at $8.99 during a trade that took place back on Mar 04 ’25, which means that BASTA JAMES is holding 111,925 shares at $23,122 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -9.23 for the present operating margin
- 0.91 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -8.97. The total capital return value is set at -0.49. Equity return is now at value -54.00, with -41.66 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -1.66.
Currently, EBITDA for the company is -523.98 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 17.0. The receivables turnover for the company is 6.8for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.77.
Conclusion
To sum up, Intellia Therapeutics Inc (NTLA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
